米国FDA/COVID-19絡みのガイダンス等の発出と更新(2021年2月22日付)
※追記更新(2021.02.24)
※追記更新(2021.02.26)
※追記更新(2021.03.11)
2/22付の米国FDAによるCOVID-19絡みガイダンス等の発出について、筆者のお好みでお伝えします。
関係者および興味のある方は、下記URLsの更新通知等をご参照ください。
l2/22付Updated「COVID-19 Vaccines」
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
l2/22付News Release「Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants」
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus
[上記関連ニュース記事]
l2/22付RAPS「FDA unveils plans to tackle COVID variants」
https://www.raps.org/news-and-articles/news-articles/2021/2/fda-unveils-plans-to-tackle-covid-variants
l2/22付最終ガイダンス「Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID 19 Public Health Emergency」
https://www.fda.gov/media/146173/download
l2/22付改訂ガイダンス「COVID-19: Developing Drugs and Biological Products for Treatment or Prevention」
https://www.fda.gov/media/137926/download
[2/24付追記更新:上記関連ニュース記事]
l2/23付RAPS「FDA's COVID therapeutics, mAbs guidance accounts for variants」
https://www.raps.org/news-and-articles/news-articles/2021/2/fdas-covid-therapeutics-mabs-guidance-accounts-for
l2/23付Outsourcing-Pharma.com「Developing vaccines and therapeutics for virus variants: FDA releases new guidance 」
https://www.outsourcing-pharma.com/Article/2021/02/23/Developing-vaccines-and-therapeutics-for-virus-variants-FDA-releases-new-guidance
l2/23付BioPharmaReporter.com「Findings of new study may help inform the design of next-generation COVID-19 vaccines, as new variants emerge 」
https://www.biopharma-reporter.com/Article/2021/02/23/Findings-of-new-study-may-help-inform-the-design-of-next-generation-COVID-19-vaccines-as-new-variants-emerge
l2/22付最終ガイダンス「Emergency Use Authorization for Vaccines to Prevent COVID-19」
https://www.fda.gov/media/142749/download
[上記関連ニュース記事]
l2/22付RAPS「FDA updates EUA guidance, addressing vaccines against COVID variants」
https://www.raps.org/news-and-articles/news-articles/2021/2/fda-updates-eua-addressing-vaccines-against-covid
[2/26付追記更新:上記関連ニュース記事]
l2/25付BioPharmaReporter.com「Pfizer and BioNTech start trialing booster shot for COVID-19 vaccine 」
https://www.biopharma-reporter.com/Article/2021/02/25/Pfizer-and-BioNTech-start-trialing-booster-shot-for-COVID-19-vaccine
l2/22付American Pharmaceutical Review「FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants」
https://www.americanpharmaceuticalreview.com/Specialty/Formulation_Development/1315-News/573477-FDA-Issues-Policies-to-Guide-Medical-Product-Developers-Addressing-Virus-Variants/?catid=6262
[3/11付追記更新:上記関連ニュース記事]
l3/10付ECA/GMP News「COVID-19 Vaccines, Tests and Therapeutics - Recommendations for Handling Emerging Virus Variants」
https://www.gmp-compliance.org/gmp-news/cov19-vaccines-tests-and-therapeutics-recommendations-for-handling-emerging-virus-variants
l2/22付最終ガイダンス「Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests」
https://www.fda.gov/media/146171/download
[上記関連ニュース記事]
l2/22付RAPS「COVID test developers get variant-related FDA guidance」
https://www.raps.org/news-and-articles/news-articles/2021/2/covid-test-developers-get-variant-related-fda-guid
l2/22付Updated「In Vitro Diagnostics EUAs」
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular
l2/22付Updated「Personal Protective Equipment EUAs」
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/personal-protective-equipment-euas#exhibit1
l2/22付Updated「Notifications and Emergency Use Authorizations: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/notifications-and-emergency-use-authorizations-faqs-testing-sars-cov-2
l2/22付Updated「Removal Lists of Tests that Should No Longer Be Used and/or Distributed for COVID-19: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/removal-lists-tests-should-no-longer-be-used-andor-distributed-covid-19-faqs-testing-sars-cov-2
[全体に関するニュース記事]
l2/22付BioPharmaReporter.com「Pfizer/BioNTech to trial COVID-19 vaccine in pregnant women and children 」
https://www.biopharma-reporter.com/Article/2021/02/22/Pfizer-BioNTech-to-trial-COVID-19-vaccine-in-pregnant-women-and-children
l2/22付BioPharmaReporter.com「Pfizer/BioNTech COVID-19 vaccine can be stored at standard freezer temperature for 2 weeks, say companies 」
https://www.biopharma-reporter.com/Article/2021/02/22/Standard-freezer-temperatures-for-Pfizer-BioNTech-COVID-19-vaccine
※追記更新(2021.02.26)
※追記更新(2021.03.11)
2/22付の米国FDAによるCOVID-19絡みガイダンス等
関係者および興味のある方は、下記URLsの更新通知等をご参照
l2/22付Updated「COVID-19 Vaccines」
https://www.fda.gov/emergency-
l2/22付News Release「Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants」
https://www.fda.gov/news-
[上記関連ニュース記事]
l2/22付RAPS「FDA unveils plans to tackle COVID variants」
https://www.raps.org/news-and-
l2/22付最終ガイダンス「Development of Monoclonal Antibody Products Targeting SARS-CoV-2, Including Addressing the Impact of Emerging Variants, During the COVID 19 Public Health Emergency」
https://www.fda.gov/media/
l2/22付改訂ガイダンス「COVID-19: Developing Drugs and Biological Products for Treatment or Prevention」
https://www.fda.gov/media/
[2/24付追記更新:上記関連ニュース記事]
l2/23付RAPS「FDA's COVID therapeutics, mAbs guidance accounts for variants」
https://www.raps.org/news-and-
l2/23付Outsourcing-Pharma.com「De
https://www.outsourcing-
l2/23付BioPharmaReporter.com「Fin
https://www.biopharma-
l2/22付最終ガイダンス「Emergency Use Authorization for Vaccines to Prevent COVID-19」
https://www.fda.gov/media/
[上記関連ニュース記事]
l2/22付RAPS「FDA updates EUA guidance, addressing vaccines against COVID variants」
https://www.raps.org/news-and-
[2/26付追記更新:上記関連ニュース記事]
l2/25付BioPharmaReporter.com「Pfi
https://www.biopharma-
l2/22付American Pharmaceutical Review「FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants」
https://www.
[3/11付追記更新:上記関連ニュース記事]
l3/10付ECA/GMP News「COVID-19 Vaccines, Tests and Therapeutics - Recommendations for Handling Emerging Virus Variants」
https://www.gmp-compliance.
l2/22付最終ガイダンス「Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests」
https://www.fda.gov/media/
[上記関連ニュース記事]
l2/22付RAPS「COVID test developers get variant-related FDA guidance」
https://www.raps.org/news-and-
l2/22付Updated「In Vitro Diagnostics EUAs」
https://www.fda.gov/medical-
l2/22付Updated「Personal Protective Equipment EUAs」
https://www.fda.gov/medical-
l2/22付Updated「Notifications and Emergency Use Authorizations: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-
l2/22付Updated「Removal Lists of Tests that Should No Longer Be Used and/or Distributed for COVID-19: FAQs on Testing for SARS-CoV-2」
https://www.fda.gov/medical-
[全体に関するニュース記事]
l2/22付BioPharmaReporter.com「Pfi
https://www.biopharma-
l2/22付BioPharmaReporter.com「Pfi
https://www.biopharma-
コメント
/
/
/
コメント